You are here

Home » Content

KOMPANSE KRONİK BÖBREK YETMEZLİKLİ HASTALARDA SERUM LIPOPROTEIN (a) DÜZEYİ

SERUM LIPOPROTEIN (a) LEVELS IN PATIENTS WITH CHRONIC RENAL FAILURE NOT RECEIVING DIALYSIS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1996

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Lipid abnormalities contribute to the increase in cardiovascular morbidity and mortality in chronic re¬nal failure (CFR) patients with or without dialysis. Li-poprotein (a) and, a unique lipoprotein has been shown to be an independent risk factor for the deve¬lopment of cardiovascular disease in general popula¬tion. This study was planned to assess the serum le¬vels of Lp(a) in predialytic CFR patients. In this study, lipid andLp(a) levels were measured in 27pre-dialytic CFR patients consisting of 14 males, 13 fema¬les and in age-and sex-matched thirty one controls. In CFR patients, HDL chol esterol level were lower and apo B were higher as compared to the control group. Moreover, Lp(a) was found to be prominently higher in CFR patients than in controls. There was a signifi¬cant positive correlation between Lp(a) levels and the amount of proteinuria. Our data suggest that increa¬sed Lp(a) level along with low level of HDL choleste¬rol and high level of Apo B may pose a significant risk factor for atherosclerotic cardiovascular disease in CFR patients.
Bookmark/Search this post with
Abstract (Original Language): 
KBY'li hastalarda sık rastlanan lipoprotein metabolizması anormallikleri ve hiperlipidemi, ateroskle-rotik kalb ve damar hastalığı riskini artırmaktadır. Çalışmamızda, 27 KBY'li hastada lipoprotein (a) ve diğer apoplipoproteinlerin düzeyleri değerlendirilmiş ve yaş ve cins uyumlu 31 kişiden oluşan kontrol grubu ile karşılaştırılmıştır. KBY'li hastalarda HDL-Kolesterol düzeyi düşük, apoprotein B ve lipoprotein (a) düzeyleri yüksek bulunmuştur. İdrar ile protein kaybı ve Lp (a) arasında anlamlı bir ilişki saptanmış¬tır. Diğer apoplipoprotein anormallikleri ile birlikte, bağımsız bir risk faktörü olan serum Lp (a) düzeyin¬deki belirgin yükselme, KBY'li hastalarda aterosklero-tik olayın hızlanmasına katkıda bulunabilir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_111.pdf
  • 1
11-15
  • Turkish

REFERENCES

References: 

1. Kandoussi A, Cachera C, Pagniez D, Dracon M, Fruc-hart JC and Tacket A. Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD. Kidney Int 1992; 42: 424-425.
2. Barbagallo CM, Averna MR, Sparacino V, et al. Lipop-rotein (a) levels in end-stage renal failure and renal transplantation. Nephron 1993; 64: 560-564.
3. Goldwasser P, Michel M, Collier J, et al. Prealbumin and lipoprotein (a) in hemodialysis: Relationship with paitent and vascular access survival. Am J Kidney Dis 1993;
22(1): 215-225.
4. Creessman MD, Heyka RJ, Paganini EP, et al. Lipopro-tein (a) Is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86(2): 475-483.
5. Senti M, Romero R, Pedro-Botet J, et al. Lipoprotein anormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41: 1394-1399.
6. Thillet J, Faucher C, Issad B, et al. Lipoprotein (a) in pa¬tients treated by Continuous Ambulatory Peritoneal Di¬alysis. Am J Kidney Dis 1993; 22(1): 226-232.
7. Steinmeta A, Kirklies A, Schlosser G, et al. Lipoprotein (a), Low-density, intermediate density lipoprotein, and blood pressure in a young male population. Clin Investig
1993;71:145-149.
8. Watts GF, Kearney EM, Taub NA, et al. Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia. J Clin Pat-
hol 1993; 46: 267-270.
9. Rader DJ, Cain W, Zech LA, et al. Variation in lipopro-tein (a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of li-poprotein (a) production. J Clin Invest 1993; 91: 443¬447.
10. Armstrong VW, Cremer P, Eberle E, et al. The associati¬on between serum Lp (a) concentrations and angiograp-hically assessed coronary atherosclerosis. Atherosclero¬sis 1986; 62: 249-257.
11. Murphy BG, McNamee P, Duly E, et al. Increased serum apolipoprotein (a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis.
Atherosclerosis 1992; 93: 53-57.
12. Parra HJ, Mezdour H, Cachera C, et al. Lp (a) lipoprote-in in patients renal failure treated by hemodialysis. Clin
Cheml987;33(5):721.
13. Cheung AK, Wu LL, Kablita C and Leypoldt JK: Athe-
rogenic lipids and lipoproteins in hemodialysis patients.
Am J Kidney Dis 1993; 22(2): 271-276.
14. Hajjar KA, Gavish D, Breslow JL and Nachman RL. Li-poprotein (a) modulation of endothelial cell surface fibri-nolysis and its potential role in atherosclerosis. Nature
1989; 339: 303-305.
15. Sandkamp M, Funke H, Schulte H, et al. Lipoprotein (a) is an independent risk factor for myocardial infarction at
a yong age. Clin Chem 1990; 36(1): 20-23.
16. Craig WY, Poulin SE, Forster NR, et al. Effect of sample storage on the assay of lipoprotein (a) by commercially available rodial immunodiffusion and enzyme-linked im-munosorbent assay kits. Clin Chem 1992; 38(4): 550¬553.
17. Eaton DL, Fless GM, Kohr WJ, et al. Partial aminoacid sequence of apolipoprotein (a) shows that at is homolo¬gous to plasminogen. Proc Natl Acad Sci USA 1987;
84(10): 3224-3228.
18. Genest J, McNamara JR, Ordovas JM et al. Lipoprotein cholesterol, apolipoprotein A-l and B lipoprotein (a) ab¬normalities in man with premature coronary artery disea¬se. J Am Coll cardiol 1992; 19: 792-802.
19. Uterma G. The mysteries of lipoprotein (a). Science
1989; 246(4932): 904-910.
20. Scanu AM. Lp(a) as a marker for coronary heart disease
risk. Clin Cardiol 1991; 14(2-1): 135-9.
21. Breckenridge WC. The role of lipoproteins and apoli-poproteins in prediction of coronary heart disease risk.
Clin Invest Med 1990; 13(4): 196-201.
22. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J. Lipoprotein (a) levels in chronic renal disease states, di¬alysis and transplantation. Aust NZ J Med 1992; 22(3):
243-248.
14
23. Webb AT, Plant M, Reaveley DA, et al. Lipid and lipop-rotein (a) concentrations in renal transplant patients. Nephrol Dial Transplant 1992; 7(7): 636-641.
24. Webb AT, Reaveley DA, O'Donnell M, et al. Does
cyclosporine increase lipoprotein (a) concentrations in renal transplant recipients ? Lancet 1993; 341: 268-270.
25. Heimann P, Josephson MA, Fellner SK, et al. Elevated lipoprotein (a) levels in renal transplantation and hemo-
dialysis. Am J Nephrol 1991; 11(6): 470-474.
26. Black IW, Wilcken DEL. Decreases in a lipoprotein (a) after renal transplantation: Implications for lipoprotein
(a) metabolism. Clin Chem 1992; 38(3): 353-357.
27. Keane WF. Lipids ant the kidney. Kidney Int 1994; 46:
910-920.
28. Joven C, Villabona C, Vilella E. Pattern of hyperlipopro-teinemia in human nefrotic syndrom: Influence of renal failure and diabetes mellitus. Nephron 1993; 64: 565¬569.
29. Kcstner GM, Gavish D, Leopold et al. HMG CoA reduc-tase inhibitors lower LDL cholesterol without reducing
Lp(a) levels. Circulation 1989; 80: 1313-9.
30.
Siileymanla
r G, Sapan M, Yılmaz H, et al. Serum lipop-roteins in renal transplant patients: The effect of cyclos-porine on lipoprotein (a). Transplant Proc 1994; 26: 2637-2638.
31. Yılmaz H, Siileymanlar G, Altinayak Ersoy FF, et al. Ef¬fect of L-Carnitine on die lipid profile of hemodialysis patients. XIII th International Congress of Nephrology,
Madrid (Spain), July 2-6, 1995.

Thank you for copying data from http://www.arastirmax.com